In the past couple of years, the UK has witnessed a revolution in clinical fat‑decline treatment options — in the introduction of semaglutide (Wegovy®) on the increasing attractiveness of tirzepatide (Mounjaro®). Now, An additional title is drawing notice in both of those scientific and community